New Breakthrough in Peanut Allergy Treatment: Epicutaneous Immunotherapy Shows Promise

Strategic Insights -

Researchers have made significant progress in developing a novel treatment for peanut allergy, using epicutaneous immunotherapy (EPIT). This approach promotes tolerance to food allergens by harnessing the power of the cutaneous immune system. The University of North Carolina's research team, led by A. Wesley Burks, has been working on EPIT, with the goal of creating a clinically practical and effective treatment option for peanut allergy.

Key Takeaways:

  • The new treatment, Viaskin Peanut, uses an occlusive patch with a condensation chamber to solubilize dry antigen on the patch, which is then absorbed and captured by skin Langerhans cells.
  • This form of EPIT does not disrupt the skin barrier, avoiding a proinflammatory cytokine response and limiting systemic allergen exposure.
  • Extensive preclinical research suggests that Viaskin Peanut has a distinct mechanism of desensitization, including the potential for disease modification, driven by a unique population of regulatory T cells.
  • Numerous clinical studies have demonstrated desensitization and reductions in reaction severity, particularly in children aged 1 through 11 years.
  • The treatment has a favorable safety profile, with mostly mild-to-moderate skin reactions that decrease over time.
  • Financial support for this research came from DBV Technologies.
  • The research has been peer-reviewed and published in the journal Allergy.

Statistics:

  • The University of North Carolina's research team conducted extensive preclinical research on Viaskin Peanut.
  • Clinical studies of Viaskin Peanut demonstrated desensitization and reductions in reaction severity in 1 through 11 year-old children.
  • The treatment has a favorable safety profile, with mostly mild-to-moderate skin reactions that decreased over time.
  • Financial support for this research came from DBV Technologies.

Sources:

  • Epuckland Immunotherapy for the Treatment of Peanut Allergy (Allergy, 2024)
  • University of North Carolina, School of Medicine, Dept. of Pediatrics, Division of Pediatric Allergy and Immunology
  • A. Wesley Burks, Mayuran Ravindran, Edwin H. Kim, Hugh A. Sampson, Katharine J. Bee, Todd D. Green (researchers)
  • DBV Technologies (financial supporter)
  • NewsRx. Studies from University of North Carolina in the Area of Allergies Reported (Epicutaneous Immunotherapy for the Treatment of Peanut Allergy). Immunotherapy Weekly. October 23, 2024; p 5812.